SOUTH SAN FRANCISCO, Calif.,
Feb. 22, 2021 /PRNewswire/ --IDEAYA
Biosciences, Inc. (NASDAQ: IDYA), a synthetic lethality-focused
precision medicine oncology company committed to the discovery and
development of targeted therapeutics, announced IDEAYA's inaugural
Synthetic Lethality Investor Day, with scientific presentations
from IDEAYA, GlaxoSmithKline (GSK) and several Key Opinion Leaders,
will be held virtually on Tuesday, April 20,
2021, at 1:00 pm - 3:00 pm ET
/ 10:00 am - 12:00 pm PT.
Scientific Presenters / Participants will include:
IDEAYA Biosciences:
- Michael Dillon, Ph.D.,
Senior Vice President, Chief Scientific Officer
- Mark Lackner, Ph.D., Senior
Vice President, Head of Biology and Translational Sciences
- Matt Maurer, M.D., Vice
President, Head of Clinical Oncology and Medical Affairs
GlaxoSmithKline:
- Benjamin Schwartz, Ph.D.,
Vice President, Head of Oncology Synthetic Lethality Research
Unit
Key Opinion Leaders / IDEAYA Scientific Advisors:
- Alan D'Andrea, M.D., Director, Center of DNA Damage and
Repair, Dana Farber Cancer Institute of Harvard Medical School
- William Sellers, M.D., Core
Institute Member and Director of the Cancer Program of the Broad
Institute of MIT and Harvard
The agenda will focus on IDEAYA/GSK partnered and IDEAYA
wholly-owned Synthetic Lethality programs, including IDE397, a
potential best-in-class methionine adenosyltransferase 2A (MAT2A)
inhibitor being evaluated in a Phase 1 clinical trial targeting
methylthioadenosine phosphorylase (MTAP) deletion, which is
prevalent in approximately 15% of all solid tumors. Agenda
topics will also include poly(ADP-ribose) gylcohydrolase (PARG), a
potential first-in-class wholly-owned program, and the IDEAYA / GSK
partnered Polymerase Theta (Pol Theta) program. A Development
Candidate is targeted for each of the PARG and PolTheta programs in
2021.
Agenda Topics:
- Synthetic Lethality: An Emerging Area within Precision
Medicine and GSK-IDEAYA Partnership
- IDE397 Phase 1 Program: Targeting MAT2A in MTAP-Deleted
Tumors
- Werner Helicase: Compelling Synthetic Lethality Target
- Pol Theta: Key Target in MMEJ DNA Damage Repair Pathway
- PARG: Novel Target in Clinically Validated Pathway
"We believe IDEAYA's inaugural Synthetic Lethality Investor Day
with presenters from IDEAYA, GSK and several academic luminaries in
the field will be an exciting forum for the scientific, analyst,
and investor communities. We will discuss key biological insights
for several potential first-in-class targets, including
PARG, Pol Theta, and Werner Helicase, as well as the
competitive differentiation and clinical development plan of
IDE397, a Phase 1 MAT2A inhibitor pursuing the MTAP-deletion
patient population," said Yujiro S.
Hata, President and Chief Executive Officer of IDEAYA
Biosciences.
Additional information on the IDEAYA Synthetic Lethality
Investor Day and registration for the event is available on
IDEAYA's website at https://ir.ideayabio.com/events.
About IDEAYA Biosciences
IDEAYA is a synthetic
lethality-focused precision medicine oncology company committed to
the discovery and development of targeted therapeutics for patient
populations selected using molecular diagnostics. IDEAYA's
approach integrates capabilities in identifying and validating
translational biomarkers with drug discovery to select patient
populations most likely to benefit from its targeted
therapies. IDEAYA is applying its early research and drug
discovery capabilities to synthetic lethality – which represents an
emerging class of precision medicine targets.
Forward-Looking Statements
This press release contains
forward-looking statements, including, but not limited to,
statements related to (i) potential first-in-class and
best-in-class status, (ii) the timing, content and participants
of the Synthetic Lethality Investor Day, and (iii) the
competitive differentiation of IDE397. Such forward-looking
statements involve substantial risks and uncertainties that could
cause IDEAYA's preclinical and clinical development programs,
future results, performance or achievements to differ significantly
from those expressed or implied by the forward-looking statements.
Such risks and uncertainties include, among others, the
uncertainties inherent in the drug development process, including
IDEAYA's programs' early stage of development, the process of
designing and conducting preclinical and clinical trials, the
regulatory approval processes, the timing of regulatory filings,
the challenges associated with manufacturing drug products,
IDEAYA's ability to successfully establish, protect and defend its
intellectual property, the effects on IDEAYA's business of the
worldwide COVID-19 pandemic, and other matters that could affect
the sufficiency of existing cash to fund operations. IDEAYA
undertakes no obligation to update or revise any forward-looking
statements. For a further description of the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to the business of IDEAYA in general, see IDEAYA's recent
Quarterly Report on Form 10-Q filed on November 12, 2020 and any current and periodic
reports filed with the U.S. Securities and Exchange
Commission.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/ideaya-biosciences-announces-inaugural-synthetic-lethality-investor-day-301231992.html
SOURCE IDEAYA Biosciences, Inc.